Psilocybin

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

Retrieved on: 
Monday, June 14, 2021

The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.

Key Points: 
  • The COPE program, launched in March, aims to create the worlds first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including psilocybin, LSD, DMT, and 5-MeO-DMT, amongst others.
  • COPE data is available to InterVivo sponsors via a partnership between Mindset and InterVivo that will allow all parties to benefit from the use of COPE data.
  • The COPE program data sets have been carefully built in partnership with InterVivos industry leading pre-clinical scientific team.
  • For detailed information on the COPE Benchmark data set, please contact Sal Lemus, Director of Sales and Marketing at InterVivo.

Bright Minds Biosciences to Present at the H.C. Wainwright Virtual Conference Psychedelics in Psychiatry and Beyond

Retrieved on: 
Friday, June 11, 2021

The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast beginning at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Bright Minds Biosciences to Present at the 2021 LD Micro Invitational XI

Retrieved on: 
Wednesday, June 9, 2021

The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.

Key Points: 
  • The presentation will be webcast live at the aforementioned time and available for 7 days thereafter using the link provided above.
  • Bright Minds is focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain.
  • Bright Minds has a portfolio of next generation serotonin agonists designed to precisely target abnormalities in neurocircuitry that lead to dysfunctional behaviors.
  • Bright Minds drugs extenuate the therapeutic aspects of psychedelic and other serotonergic compounds while minimizing the side effects thereby creating superior drugs to first generation compounds, such as psilocybin.

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Retrieved on: 
Tuesday, June 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinsons, Bipolar disorder, and chronic back pain.

Key Points: 
  • This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinsons, Bipolar disorder, and chronic back pain.
  • Eric Weisblum, CEO of Silo Pharma commented Inflammation is a common mechanism across numerous physical diseases.
  • Inflammation has specifically been implicated in the pathophysiology of Parkinsons Disease,chronic pain, and bipolar disorder.
  • A better understanding of the anti-inflammatory effects of psilocybin has potential to allow for optimization and personalization of psilocybin treatment.

Pharmadrug's Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

Retrieved on: 
Monday, June 7, 2021

The European Slim Winkel online store will sell psilocybin truffles as well as functional mushrooms in The Netherlands.

Key Points: 
  • The European Slim Winkel online store will sell psilocybin truffles as well as functional mushrooms in The Netherlands.
  • The website will also service other parts of Europe, but without the access to psilocybin truffles.
  • Secondly, it will enable the company to continue to curate quality products, which will eventually include its own branded psilocybin truffles in The Netherlands.
  • Thirdly, it will enable Super Smart to continue to develop its psilocybin supply chain.

COMPASS Pathways and Kings College London publish cognition results from COMP360 psilocybin study in healthy volunteers

Retrieved on: 
Thursday, June 3, 2021

The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg) compared with placebo in 89 healthy male and female adult volunteers.

Key Points: 
  • The study looked at the effects of two doses of COMP360 psilocybin (10mg and 25mg) compared with placebo in 89 healthy male and female adult volunteers.
  • The participants were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29).
  • The results are encouraging and we are looking forward to reporting data from our phase IIb trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) later this year.
  • Dr Rucker said: This study, the largest randomised placebo-controlled trial of psilocybin to date, found that COMP360 psilocybin had no clinically-relevant negative effect on cognitive function.

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic Medicine

Retrieved on: 
Thursday, June 3, 2021

The selection of Mindsets first lead candidate, MSP-1014, is a significant milestone in our clinical journey.

Key Points: 
  • The selection of Mindsets first lead candidate, MSP-1014, is a significant milestone in our clinical journey.
  • Our next generation psychedelic compounds represent the flourishing evolution of therapeutics to effectively address neurological and neuropsychiatric disorders, said James Lanthier, CEO of Mindset.
  • Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs.
  • Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

NeonMind to Commence Trading on the OTCQB Venture Market

Retrieved on: 
Friday, May 28, 2021

Vancouver, British Columbia--(Newsfile Corp. - May 28, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FFE: 6UF) ("NeonMind"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that its shares will commence trading on the OTCQB Venture Market (the "OTCQB") on May 28, 2021, under the symbol "NMDBF".

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - May 28, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FFE: 6UF) ("NeonMind"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, is pleased to announce that its shares will commence trading on the OTCQB Venture Market (the "OTCQB") on May 28, 2021, under the symbol "NMDBF".
  • With more compliance and quality standards, the OTCQB provides investors improved visibility to enhance trading decisions.
  • The OTCQB is recognized by the United States Securities and Exchange Commission as an established public market providing public information for analysis and value of securities.
  • "With this OTCQB listing, NeonMind has achieved a significant milestone in its mission to advance its psilocybin drug development programs," said Robert Tessarolo, President & CEO of NeonMind.

Diamond Therapeutics to present groundbreaking study at NIH event

Retrieved on: 
Thursday, May 27, 2021

Diamond believes these findings may help unlock the use of low-dose psilocybin for the treatment of psychiatric disorders, including anxiety and depression.

Key Points: 
  • Diamond believes these findings may help unlock the use of low-dose psilocybin for the treatment of psychiatric disorders, including anxiety and depression.
  • The study was within the top five percent of all research outputs in February 2021, as scored by Altmetric.
  • The NIH Psilocybin Research Speaker Series runs from April 22 to June 10, 2021.
  • Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.640241
    Diamond Therapeutics is a psychedelic drug development company based in Toronto.

Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms

Retrieved on: 
Tuesday, May 25, 2021

Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners.

Key Points: 
  • Under the new guidance from Health Canada, Mydecine will begin construction of expanded cultivation facilities in an effort to scale its supply of pharmaceutical grade psilocybin for both internal clinical research and its industry partners.
  • The increased cultivation will also allow the Company to more efficiently and quickly study the medical utility of naturally occurring psilocybin and psilocybin-like compounds.
  • Nature has produced a diversity of psilocybin producing fungi, all with their own unique chemistry and much of this diversity remains unstudied or undiscovered.
  • The expansion of our cultivation capabilities will give us a unique lens into better understanding this incredible diversity and how it may be utilized in a therapeutic setting.